Home Biosimilar Antibodies Immunology & Inflammation CD markers Omburtamab (Anti-B7-H3 / CD276)
For research use only. Not for use in humans.

Omburtamab (Anti-B7-H3 / CD276)

Synonyms: null

Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD.

Omburtamab (Anti-B7-H3 / CD276)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A298601 Purity: 99% Protein concentration: 8.3mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD.
References

Product Details

CAS No. 1895083-75-6
Molecular Weight 145.04
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07408063 RECRUITING Drug: GSK5764227|Drug: Dostarlimab Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma University Health Network, Toronto 2026-04-27 PHASE2
NCT07698899 RECRUITING Recurrent Medulloblastoma; Refractory Medulloblastoma; CNS Metastases; Central Nervous System Metastasis Memorial Sloan Kettering Cancer Center 2026-07-02 PHASE1
NCT05142189 RECRUITING Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel Non-Small Cell Lung Cancer BioNTech SE 2022-06-17 PHASE1
NCT04432649 NOT_YET_RECRUITING Solid Tumor Shenzhen Geno-Immune Medical Institute 2027-06-01 PHASE1; PHASE2
NCT04637503 NOT_YET_RECRUITING Neuroblastoma Shenzhen Geno-Immune Medical Institute 2026-12-31 PHASE1; PHASE2
NCT07231081 RECRUITING Solid Tumors Tcelltech Inc. 2025-10-16 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-04-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.